preamble_12
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products · European Union
(2) patients suffering from rare conditions should be entitled to the same quality of treatment as other patients; it is therefore necessary to stimulate the research, development and bringing to the market of appropriate medications by the pharmaceutical industry; incentives for the development of orphan medicinal products have been available in the United States of America since 1983 and in Japan since 1993;
← preamble_11 · All articles · preamble_13 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-21 · Text as adopted (Official Journal); later amendments are not incorporated in this text.